23 Patents
- US126066032026IL-13 Receptor Alpha 2 Targeted, Zetakine Directed T Cell Immunotherapy
Seattle Children's Hospital
0 cites - 0 cites
- 0 cites
- 0 cites
- US124212942025Truncated Epiderimal Growth Factor Receptor (egfrt) for Transduced T Cell Selection
City Of Hope
0 cites - US123124162025Fluorescein-specific Cars Exhibiting Optimal T Cell Function Against FL-PLE Labelled Tumors
Seattle Children's Hospital
0 cites - 0 cites
- US122583972025Production of Engineered T-cells by Sleeping Beauty Transposon Coupled with Methotrexate Selection
University Of Washington
0 cites - 0 cites
- US122330902025Bispecific Or-gate Chimeric Antigen Receptor Responsive to CD20 and CD19
Seattle Children's Hospital
0 cites - US122264352025Bispecific Or-gate Chimeric Antigen Receptor Responsive to CD20 and CD19
Seattle Children's Hospital
0 cites - 0 cites
- 0 cites
- US121730712024Methods and Compositions Comprising B7H3 Chimeric Antigen Receptors
Seattle Children's Hospital
0 cites - US121520792024Nucleic Acids Encoding IL-13 Receptor Alpha 2 (il13ra2) Chimeric Antigen Receptor for Tumor Specific T Cell Immunotherapy
Seattle Children's Research Institute
0 cites - US120982082024Early Intervention Methods to Prevent or Ameliorate Toxicity
Seattle Children's Hospital
0 cites - US120534912024Bispecific Or-gate Chimeric Antigen Receptor Responsive to CD19 and CD20
Seattle Children's Hospital
0 cites - US119446482024Bispecific Or-gate Chimeric Antigen Receptor Responsive to CD19 and CD20
Seattle Children's Hospital
0 cites - US118516492023Generating Mammalian T Cell Activation Inducible Synthetic Promoters (SYN+PRO) to Improve T Cell Therapy
Seattle Children's Hospital
0 cites - 0 cites
- 0 cites
- US117608042023Early Intervention Methods to Prevent or Ameliorate Toxicity
Seattle Children's Hospital
0 cites - US116492882023Phospholipid Ether (PLE) CAR T Cell Tumor Targeting (CTCT) Agents
Seattle Children's Hospital
0 cites